Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib
-
Published:2024-07
Issue:
Volume:
Page:
-
ISSN:2152-2650
-
Container-title:Clinical Lymphoma Myeloma and Leukemia
-
language:en
-
Short-container-title:Clinical Lymphoma Myeloma and Leukemia
Author:
Gagelmann NicoORCID,
Bose PrithvirajORCID,
Gupta Vikas,
McLornan Donal P.,
Vachhani PankitORCID,
Al-Ali Haifa-Kathrin,
Ali Haris,
Treskes PhilippORCID,
Buckley Sarah,
Roman-Torres Karisse,
Scott Bart
Reference25 articles.
1. Myelofibrosis
2. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)
3. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis;Harrison;Leukemia,2016
4. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study;Harrison;Lancet Haematol,2017
5. Cytopenic myelofibrosis: prevalence, relevance, and treatment;Vachhani;Expert Opin Pharmacother,2023